We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Oral Cambinol Treatment Shows Potential for Blocking Development of AD

By LabMedica International staff writers
Posted on 16 May 2018
Alzheimer's disease researchers have shown that the low molecular weight drug cambinol blocks the formation of exosomes that allow the spread of insoluble, toxic tau aggregates, which are characteristic of the neurodegenerative disorder.

Tau proteins are components of the cytoskeleton of neurons, but in Alzheimer's disease, tau proteins become abnormally modified and condense into insoluble "neurofibrillary tangles" that destroy these brain cells. More...
Furthermore, dying cells encase tau aggregates in exosome lipid vesicles, which bud off and "seed" neighboring tissues, spreading the disease.

During a screen of potential drug candidates capable of blocking the seeding of tau tangles, investigators at the University of California, Los Angeles (USA), identified the compound cambinol. Previous studies had shown that cambinol was a novel uncompetitive inhibitor of the enzyme nSMase2 (neutral sphingomyelinase 2). The enzyme nSMase2 had been found to be critically required for catalyzing the production of exosome vesicles.

The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, SIRT1/2 (silence information regulator 1 and 2). Cambinol decreased tumor necrosis factor-alpha or interleukin-1 beta-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity identified the main structural features required for nSMase2 inhibition.

In a paper published in the April 9, 2018, online edition of the journal Biochemical and Biophysical Research Communications, the investigators demonstrated that cambinol was an inhibitor of cell-to-cell tau propagation. In vitro data revealed that cambinol inhibited nSMase2 enzyme activity in dose response fashion, and suppressed exosome vesicle production while reducing tau seed propagation. In vivo testing in mice showed that cambinol could reduce the nSMase2 activity in the brain after oral administration.

"Over 200 molecules have been tested as disease-modifying Alzheimer's therapy in clinical trials, and none has yet attained the Holy Grail," said senior author Dr. Varghese John, associate professor of neurology at the University of California, Los Angeles. "Our paper describes a novel approach to slow Alzheimer's progression by showing it is possible to inhibit propagation of pathologic forms of tau."

Decreased nSMase2 catalytic activity was observed in the brains of mice given oral cambinol. "Getting molecules into the brain is a big hurdle, because most drugs do not penetrate the blood-brain barrier, said Dr. John. "Now we know we can treat animals with cambinol to determine its effect on Alzheimer's pathology and progression."

Related Links:
University of California, Los Angeles


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Automated Cell Culture Chemistry Analyzer
BioProfile FLEX2 Basic
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.